A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft tissue infections. These infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among ICU patients.
Age range
90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
A. baumannii antibiotic susceptibility profile
Timeframe: October 2024 to December 2025
Isolation and identification of A. baumannii from different clinical samples
Timeframe: October 2024 to December 2025
A. baumannii strains which produce biofilm
Timeframe: October 2024 to December 2025
Ability of ZnO NPs to inhibit the phenomenon of biofilm formation by MDR A. baumannii strains
Timeframe: October 2024 to December 2025
The effect of ZnO NPs on the expression of some efflux pump genes and biofilm related genes in MDR A. baumannii strains
Timeframe: October 2024 to December 2025